Baseline characteristics and results of included trials
| Copernicus1213 | Galileo11 | Cruise910 | Geneva6–8 | Epstein et al42–44 | Score23–36 |
|---|---|---|---|---|---|
| Baseline similarities | |||||
| Number (%) of patients | |||||
| Aflib 2 mg: 114 | Aflib 2 mg: 103 | Rani 0.5 mg: 130 | Dexa 0.7 mg: 136 | Beva 1.25 mg: 30 | Triam 4 mg: 91 |
| Sham: 73 | Sham: 68 | Sham: 130 | Sham: 147 | Sham: 30 | Obser: 88 |
| Age (years) | |||||
| Aflib 2 mg: 65.5 SD 13.6 | Aflib 2 mg: 59.9 SD 12.4 | Rani 0.5 mg: 67.6 SD 12.4 | Dexa 0.7 mg: NR | Beva 1.25 mg: 70.6 SD 12.6 | Triam 4 mg: 67.5 SD 12.0 |
| Sham: 67.5 SD 14.3 | Sham: 63.8 SD 13.3 | Sham: 65.4 SD 13.1 | Sham: NR | Sham: 70.4 SD 10.4 | Obser: 69.2 SD 12.8 |
| BCVA at baseline (SD) | |||||
| Aflib 2 mg: 50.7 SD 13.90 | Aflib 2 mg: 53.6 SD 15.8 | Rani 0.5 mg: 48.1 SD 14.6 | Dexa 0.7 mg: NR | Beva 1.25 mg: 44.4 SD 15.3 | Triam 4 mg: 51.0 SD 14.4 |
| Sham: 48.9 SD 14.42 | Sham: 50.9 SD 15.4 | Sham: 49.2 SD 14.7 | Sham: NR | Sham: 43.6 SD 16.0 | Obser: 52.1 SD 13.1 |
| Duration of MO from diagnosis to screening | |||||
| Aflib 2 mg: 2.73 SD 3.09 (in months) | Aflib 2 mg: 50.9 SD 15.4) (in days) | Rani 0.5 mg: – | Dexa 0.7 mg: NR | Beva 1.25 mg: NR | Triam 4 mg: 4.2 SD 3.6 (in months) |
| Sham: 1.88 SD 2.19 (in months) | Sham: 87.6 SD 79.1 (in days) | Sham: – | Sham: NR | Sham: NR | Obser: 4.2 SD 3.1 (in months) |
| Results | |||||
| Number (%) of patients gaining ≥15 letters improvement from baseline to 6 months | |||||
| Aflib 2 mg: 64 (56.1) | Aflib 2 mg: 62 (60.2) | Rani 0.5 mg: 62 (47.7) | Dexa 0.7 mg: 25 (18) | Beva 1.25 mg: 18 (60%) | Triam 4 mg: 18 (19.5%) (average of 4 and 8 months) |
| Sham: 9 (12.3) | Sham: 15 (22.1) | Sham: 22 (16.9) | Sham: 18 (12) | Sham: 6 (20%) | Obser: 3 (4%) (average of 4 and 8 months) |
| Number (%) of patients losing ≥15 letters of BCVA from baseline to 6 months | |||||
| Aflib 2 mg: 2 (1.8) | Aflib 2 mg: 8 (7.8) | Rani 0.5 mg: 2 (1.5) | Dexa 0.7 mg: NR | Beva 1.25 mg: 2 (6.7%) | Triam 4 mg: 19 (20.5%) (average of 4 and 8 months) |
| Sham: 20 (27.4) | Sham: 15 (22.1) | Sham: 20 (15.4) | Sham: NR | Sham: 7 (23.3%) | Obser: 31 (35.5%) (average of 4 and 8 months) |
| Mean change (SD) from baseline in BCVA | |||||
| Aflib 2 mg: 17.3 (12.8) | Aflib 2 mg: 18.0 (12.2) | Rani 0.5 mg: 14.9 (13.2) | Dexa 0.7 mg: 0.1 (NR) | Beva 1.25 mg: 14.1 SD 18.7 | Triam 4 mg: −0.15 SD 20.67 (n=85) (weight mean and SD of 4 and 8 months) |
| Sham: −4 (18) | Sham: 3.3 (14.1) | Sham: 0.8 (16.2) | Sham: −1.8 (NR) | Sham: −2.0 SD 20.5 | Obser: −9.66 SD 18.04 (n=75) (weighted mean and SD of 4 and 8 months) |
Aflib, aflibercept; BCVA, best corrected visual acuity; Dexa, dexamethasone; NR, not reported; Obser, observation; Rani, ranibizumab; Triam, triamcinolone.